Glutamate transport inhibitors as targets for treating psychosis

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 4, 2006, Pages 533-537

  Dunlop, John ^a   Marquis, Karen ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIAMINOPROPIONIC ACID; 2,3 DIAMINOPROPIONIC ACID DERIVATIVE; CYCLOSERINE; DEXTRO SERINE; DOPAMINE; EXCITATORY AMINO ACID TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; EXCITATORY AMINO ACID TRANSPORTER 3; GLUTAMATE RECEPTOR 2; GLUTAMATE RECEPTOR 3; GLUTAMATE RECEPTOR 5; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; GLYCINE TRANSPORTER 1 INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NBI 59159; NEUROLEPTIC AGENT; TRANQUILIZER; UNCLASSIFIED DRUG;

CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; EXCITOTOXICITY; HUMAN; LOCOMOTION; NERVE CELL LESION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 33846177543     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.10.005     Document Type: Review

References (26)

1. Bridges R.J., and Esslinger C.S. The excitatory amino acid transporters: pharmacological insights on substrate and inhibitor specificity of the EAAT subtypes. Pharmacol. Ther. 107 (2005) 271-285
2. Danbolt N.C. Glutamate uptake. Prog. Neurobiol. 65 (2001) 1-105
3. Gonzalez M.I., and Robinson M.B. Neurotransmitter transporters: why dance with so many partners?. Curr. Opin. Pharmacol. 4 (2004) 30-35
4. Dunlop J. Glutamate-based therapeutic approaches: targeting the glutamate transport system. Curr. Opin. Pharmacol. 6 (2006) 103-107
5. Dunlop J., and Butera J. Ligands targeting the excitatory amino acid transporters. Curr. Top. Med. Chem. 6 (2006) 1897-1906
6. Miyamoto S., et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10 (2005) 79-104
7. Millan M.J. N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology 179 (2005) 30-53
8. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 10 (2005) 40-68
9. Cartmell J., and Monn J. Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology 148 (2000) 423-429
10. Galici R., et al. A selectibe allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J. Pharmacol. Exp. Ther. 315 (2005) 1181-1187
11. Rorick-Kehn L.M., et al. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344. J. Pharmacol. Exp. Ther. 316 (2006) 905-913
12. Schoepp D.D., and Marek G.J. Preclinical pharmacology of mGlu2/3 receptor agonists: Novel agents for schizophrenia?. Curr. Drug Targets - CNS Neurol. Disord. 1 (2002) 215-225
13. Depoortere R., et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 30 (2005) 1963-1985
14. Harsing L.G.J., et al. The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Pharmacol. Biochem. Behav. 74 (2003) 811-825
15. Kinney G.G., et al. The glycine transporter type 1 inhibitor N-[3-(4′-flurophenyl)-3-(4′-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J. Neurosci. 23 (2003) 7586-7591
16. Chavez-Noriega L.E., et al. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia. Curr. Drug Targets - CNS Neurol. Disord. 1 (2002) 261-281
17. Kinney G., et al. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J. Pharmacol. Exp. Ther. 306 (2003) 116-123
18. Heresco-Levy U., and Javitt D.C. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr. Res. 66 (2004) 89-96
19. Heresco-Levy U., et al. d-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schzophrenia. Biol. Psychiatry 57 (2005) 577-585
20. Javitt D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol. Psychiatry 9 (2004) 984-997
21. Furuta A., et al. Cellular and synaptic localization of the neuronal glutamate transporters excitatory amino acid transporter 3 and 4. Neuroscience 81 (1997) 1031-1042
22. Kugler P., and Schmitt A. Glutamate transporter EAAC1 is expressed in neurons and glial cells in the rat nervous system. Glia 27 (1999) 129-142
23. McCullumsmith R.E., and Meador-Woodruff J.H. Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, amd major depressive disorder. Neuropsychopharmacology 26 (2002) 368-375
24. Schmitt A., et al. Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain. Neurosci. Lett. 347 (2003) 81-84
25. Coon T.R., et al. Design and synthesis of inhibitors of the neuronal glutamate transporter EAAT3. Society for Neuroscience, 34th Annual Meeting. 23-27 October 2004, San Diego, CA, USA (2004) (Poster 168.10)
26. Dunlop J., et al. WAY-855 (3-amino-tricyclo[2.2.1.02.6]heptane-1,3-dicarboxylic acid): a novel, EAAT2-preferring, nonsubstrate inhibitor of high-affinity glutamate uptake. Br. J. Pharmacol. 140 (2003) 839-846